|Mr. J. Kevin Buchi||Chief Exec. Officer||N/A||N/A||1955|
|Mr. Patrick M. Caldwell||Principal Accounting Officer||N/A||N/A||1962|
|Dr. Ronald Law J.D., Ph.D.||Sr. VP of Bus. Devel.||N/A||N/A||1953|
|Carl A. Valenstein||Corp. Sec.||N/A||N/A||N/A|
BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, and human lipoma, as well as uterine fibroids. In addition, the company engages in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. BioSpecifics Technologies Corp. has a development and license agreement with Endo Global Ventures. The company was founded in 1957 and is headquartered in Lynbrook, New York.
BioSpecifics Technologies Corp.’s ISS Governance QualityScore as of October 4, 2019 is 5. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 3; Compensation: 3.